Reaction profile

The FDA adverse-event record for sinus disorder nos

Name: Sinus disorder NOS - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

28 FDA reports name sinus disorder nos, a lower-volume reaction in the CVM extract (VeDDRA 1750). Plate stamps and neighbourhood peers follow.

#2033 of 2,481
by report volume (all reactions): 28
reports citing this reaction: 14.3%
death-coded share: Dog
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Sinus disorder NOS has 28 reports now versus 28 in that prior snapshot: 0 the same number of (0.0%).

Report change: +0
Death-coded reports: +0
Death-coded share: +0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Sinus disorder NOS changes

FDA AER · VeDDRA plate

Code 1750 VOL-TRACE

VOL-TRACE · DEATH-ELEV · LOWER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

VOL-TRACE 28 reports
DEATH-ELEV 14.3%
LOWER-Q #2033/2481
PHOTO-FINISH Absence seizure
SPECIES-DOG Dog · 12
DRUG-LEAD Emodepside + Praz… · 3
DESK-WIDE 19 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: Absence seizure (±0 reports)

Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.

Lower-volume neighbourhood around Sinus disorder NOS

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around Sinus disorder NOS

What the FDA AER plate says about Sinus disorder NOS

Signature read: 28 reports place Sinus disorder NOS in the lower third of FDA AER volume (#2033 of 2,481). Report volume is lower-third scale: 28 named reports in the openFDA extract. 4 of 28 reports were death-coded (14.3% of named reports, not a population mortality rate). Nearest volume peer: Absence seizure (±0 reports). Lead species Dog (12). Lead co-reported drug Emodepside + Praziquantel (3).

Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Emodepside + Praziquantel appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 12

Cat 9

Human 6

Horse 1

Breeds Most Affected

Unknown 6

Domestic Shorthair 4

Dog (unknown) 2

Dachshund - Standard Long-haired 1

Domestic Mediumhair 1

Terrier - Boston 1

Beagle 1

Cat (unknown) 1

Crossbred Canine/dog 1

Retriever - Labrador 1

Associated Drugs

Emodepside + Praziquantel 3

Maropitant Citrate 3

Gabapentin 3

Cefovecin 2

Prednisone 2

Vitamin B12 2

Trilostane 2

Frunevetmab 2

Selamectin 1

Milbemycin Oxime + Spinosad 1

Spinosad 1

Ivermectin 1

Atropine 1

Clindamycin 1

Furosemide 1

Fluconazole 1

Ceftriaxone 1

Potassium Chloride 1

Prescription Diet (Unspecified) 1

Enema 1

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Sinus disorder NOS (#2033 of 2,481 by report volume); death-coded 14.3%. PlainBreed reaction plate · report volume stamp 28 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →